covid-19 Government patient symptomatic

Glenmark gets regulatory approval for Favipiravir to treat Covid-19

Reading now: 975
www.pharmaceutical-technology.com

obtained regulatory approval to assess the drug in Phase III trials for mild to moderate Covid-19. According to the company, Favipiravir demonstrated promising clinical evidence, with positive results in mild to moderate Covid-19 cases.

Clinical improvement was observed in age groups of 20 to >90 years.The drug is said to provide rapid decrease in viral load within four days, along with quicker symptomatic and radiological improvement.

Favipiravir demonstrated up to 88% of clinical improvement in patients with mild to moderate Covid-19. Glenmark said that mild to moderate Covid-19 patients with co-morbid conditions such as diabetes and heart disease can also use the drug.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA